CJC-1295 NO DAC 5mg + IPA 5mg
CJC-1295 No DAC 5mg + IPA 5mg is a pairing of two growth hormone secretagogues with complementary mechanisms of action. CJC-1295 NO DAC acts as a Growth Hormone-Releasing Hormone analogue, while Ipamorelin (IPA) functions as a selective ghrelin receptor agonist, together providing dual-pathway stimulation in research models. Used in studies exploring growth hormone release pathways and receptor-level pharmacology.
CJC-1295 NO DAC 5mg + IPA 5mg
Sale!16%
CJC-1295 No DAC 5mg + IPA 5mg is a pairing of two growth hormone secretagogues with complementary mechanisms of action. CJC-1295 NO DAC acts as a Growth Hormone-Releasing Hormone analogue, while Ipamorelin (IPA) functions as a selective ghrelin receptor agonist, together providing dual-pathway stimulation in research models. Used in studies exploring growth hormone release pathways and receptor-level pharmacology.
$159.00
Buy more, save more!
-
Save 2%
Buy 3, get $2.50 off each
$159.00Per item: $156.50Total price: $469.50 -
Save 2%
Buy 5, get $3.75 off each
$159.00Per item: $155.25Total price: $776.25 -
Save 5%
Buy 10, get $7.50 off each
$159.00Per item: $151.50Total price: $1,515.00
$189.00$159.00
99+% PURITY
All peptides are third-party lab tested.
SECURE PAYMENT
Your payments are secure with our private security network.
FREE SHIPPING
for orders over $250
Description
Additional information
Reviews (0)
CJC-1295 NO DAC is the standard form of a synthetic growth hormone-releasing hormone analogue that does not include Drug Affinity Complex (DAC) modification.
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively targets ghrelin receptors, specifically the GHS-R1a receptor, with high binding specificity.
When combined, CJC-1295 No DAC and Ipamorelin provide a dual-pathway research model for studying growth hormone regulation through both GHRH and ghrelin signalling systems. CJC-1295 NO DAC activates GHRH receptors in the anterior pituitary, increasing cyclic adenosine monophosphate (cAMP) via adenylyl cyclase activation, while Ipamorelin stimulates ghrelin receptors through a separate G-protein coupled pathway that also elevates cAMP through an alternative mechanism. This parallel activation enables investigation of potential synergistic interactions between the two systems.
This combination is used in research to explore how complementary signalling pathways may influence growth hormone secretion patterns, including both immediate and sustained release dynamics.
Research applications include:
- Growth hormone physiology
- Receptor pharmacology
- Interaction between dual secretagogue pathways.
The 5 mg + 5 mg formulation is used to evaluate balanced activity between both components.
| Strength Variation |
|---|
There are no reviews yet.